Literature DB >> 8061930

Fibrillin secretion and microfibril assembly by Marfan dermal fibroblasts.

C M Kielty1, J E Phillips, A H Child, F M Pope, C A Shuttleworth.   

Abstract

The Marfan syndrome has been linked to the FBN1 gene encoding the microfibrillar glycoprotein fibrillin. To date, there have been no descriptions of microfibrillar abnormalities characteristic of this connective tissue disorder, although biochemical analyses have highlighted apparent abnormalities in fibrillin synthesis, secretion and processing. We have conducted a biochemical and ultrastructural investigation of fibrillin expression and assembly by a panel of dermal fibroblast lines from patients with Marfan syndrome and related diseases. The study has highlighted marked differences between cells in terms of secretion and aggregation of newly-synthesised fibrillin. In addition, electron microscopic visualization of fibrillin assemblies has clearly demonstrated for the first time the plethora of microfibrillar abnormalities that underlie this heterogeneous disorder. These data emphasize the molecular complexity that is a feature of the diverse clinical phenotypes exhibited by Marfan patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8061930     DOI: 10.1016/0945-053x(94)90008-6

Source DB:  PubMed          Journal:  Matrix Biol        ISSN: 0945-053X            Impact factor:   11.583


  9 in total

1.  Fibrillin degradation by matrix metalloproteinases: implications for connective tissue remodelling.

Authors:  J L Ashworth; G Murphy; M J Rock; M J Sherratt; S D Shapiro; C A Shuttleworth; C M Kielty
Journal:  Biochem J       Date:  1999-05-15       Impact factor: 3.857

Review 2.  The molecular genetics of Marfan syndrome and related microfibrillopathies.

Authors:  P N Robinson; M Godfrey
Journal:  J Med Genet       Date:  2000-01       Impact factor: 6.318

Review 3.  The phenotype/genotype relation and the current status of genetic screening in hypertrophic cardiomyopathy, Marfan syndrome, and the long QT syndrome.

Authors:  J Burn; J Camm; M J Davies; L Peltonen; P J Schwartz; H Watkins
Journal:  Heart       Date:  1997-08       Impact factor: 5.994

Review 4.  The molecular genetics of Marfan syndrome and related disorders.

Authors:  P N Robinson; E Arteaga-Solis; C Baldock; G Collod-Béroud; P Booms; A De Paepe; H C Dietz; G Guo; P A Handford; D P Judge; C M Kielty; B Loeys; D M Milewicz; A Ney; F Ramirez; D P Reinhardt; K Tiedemann; P Whiteman; M Godfrey
Journal:  J Med Genet       Date:  2006-03-29       Impact factor: 6.318

5.  Classical and neonatal Marfan syndrome mutations in fibrillin-1 cause differential protease susceptibilities and protein function.

Authors:  Ryan Kirschner; Dirk Hubmacher; Garud Iyengar; Jasvir Kaur; Christine Fagotto-Kaufmann; Dieter Brömme; Rainer Bartels; Dieter P Reinhardt
Journal:  J Biol Chem       Date:  2011-07-22       Impact factor: 5.157

6.  Early fibrillin-1 assembly monitored through a modifiable recombinant cell approach.

Authors:  Dirk Hubmacher; Eric Bergeron; Christine Fagotto-Kaufmann; Lynn Y Sakai; Dieter P Reinhardt
Journal:  Biomacromolecules       Date:  2014-03-07       Impact factor: 6.988

7.  Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome.

Authors:  Daniel P Judge; Nancy J Biery; Douglas R Keene; Jessica Geubtner; Loretha Myers; David L Huso; Lynn Y Sakai; Harry C Dietz
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

8.  Marfan syndrome: fibrillin expression and microfibrillar abnormalities in a family with predominant ocular defects.

Authors:  C M Kielty; S J Davies; J E Phillips; C J Jones; C A Shuttleworth; S J Charles
Journal:  J Med Genet       Date:  1995-01       Impact factor: 6.318

9.  Fifteen novel FBN1 mutations causing Marfan syndrome detected by heteroduplex analysis of genomic amplicons.

Authors:  G Nijbroek; S Sood; I McIntosh; C A Francomano; E Bull; L Pereira; F Ramirez; R E Pyeritz; H C Dietz
Journal:  Am J Hum Genet       Date:  1995-07       Impact factor: 11.025

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.